Park Square has placed David Moller, MD, as Chief Scientific Officer at Poxel SA.
{
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the appointment of David E. Moller, MD, as Chief Scientific Officer (CSO).
unknownx500
More posts by Park Square Executive Search
Recent posts from Park Square Executive Search
